[
  {
    "ts": "2025-11-06T07:00:00+00:00",
    "headline": "Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe",
    "summary": "INCHEON, Korea, November 06, 2025--Samsung Bioepis has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, in Europe.",
    "url": "https://finance.yahoo.com/news/samsung-bioepis-reaches-settlement-agreement-070000640.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "fa3a3d6e-5d39-3908-99eb-8e2569a0ce24",
      "content": {
        "id": "fa3a3d6e-5d39-3908-99eb-8e2569a0ce24",
        "contentType": "STORY",
        "title": "Samsung Bioepis Reaches Settlement Agreement for PYZCHIVA® (ustekinumab) in Europe",
        "description": "",
        "summary": "INCHEON, Korea, November 06, 2025--Samsung Bioepis has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, in Europe.",
        "pubDate": "2025-11-06T07:00:00Z",
        "displayTime": "2025-11-06T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/7a49bdfefeb7a07f0664d74a47feb882",
          "originalWidth": 1270,
          "originalHeight": 458,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5JClszrsFXRA9E1uoDDGQQ--~B/aD00NTg7dz0xMjcwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7a49bdfefeb7a07f0664d74a47feb882.cf.webp",
              "width": 1270,
              "height": 458,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vD0.OjrecitfjTPx2yujTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/7a49bdfefeb7a07f0664d74a47feb882.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/samsung-bioepis-reaches-settlement-agreement-070000640.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/samsung-bioepis-reaches-settlement-agreement-070000640.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:51:28+00:00",
    "headline": "AstraZeneca CEO bullish on record revenue numbers and US growth",
    "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
    "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
      "content": {
        "id": "0afbe5d4-9f21-3316-ab2a-9a45fb5e7450",
        "contentType": "VIDEO",
        "title": "AstraZeneca CEO bullish on record revenue numbers and US growth",
        "description": "<p>AstraZeneca's (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/AZN\">AZN</a>, <a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.L\">AZN.L</a>, <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/AZN.ST\">AZN.ST</a>) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/JNJ\">JNJ</a>), Merck (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/MRK\">MRK</a>) and Pfizer (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>). For more live coverage of the markets, watch the full episode of <em>Market Sunrise</em> and visit<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/\"> Yahoo Finance</a>.</p>",
        "summary": "AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance.",
        "pubDate": "2025-11-06T12:51:28Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab",
          "originalWidth": 4787,
          "originalHeight": 2695,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YZigCM3MtAH584LADKiEmA--~B/aD0yNjk1O3c9NDc4NzthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 4787,
              "height": 2695,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lb3cKjiVc_C_ZhL48TzyZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/f4a5d3d0-bb0e-11f0-bffb-c1aeb4364bab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/astrazeneca-ceo-bullish-record-revenue-125128988.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:30:00+00:00",
    "headline": "FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. The approval – the first under J&J leadership following its acquisition of Intra-Cellular Therapies, Inc. – provides patients with a safe and effective new treatment option that can enable a path to remission. CAPLYTA® makes it easy to start and stay on treatmen",
    "url": "https://finance.yahoo.com/news/fda-approval-caplyta-lumateperone-potential-123000377.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "4799bc13-2f23-3f80-8a0b-c6b93a1f80d5",
      "content": {
        "id": "4799bc13-2f23-3f80-8a0b-c6b93a1f80d5",
        "contentType": "STORY",
        "title": "FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder",
        "description": "",
        "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. The approval – the first under J&J leadership following its acquisition of Intra-Cellular Therapies, Inc. – provides patients with a safe and effective new treatment option that can enable a path to remission. CAPLYTA® makes it easy to start and stay on treatmen",
        "pubDate": "2025-11-06T12:30:00Z",
        "displayTime": "2025-11-06T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/2bca77195bc78302701e20c6f02a5fbd",
          "originalWidth": 400,
          "originalHeight": 38,
          "caption": "Johnson & Johnson",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FZ85NytkUmTKmOiWzw_W_g--~B/aD0zODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2bca77195bc78302701e20c6f02a5fbd.cf.webp",
              "width": 400,
              "height": 38,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ef4HGBIVATVjjNCFfw3E7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2bca77195bc78302701e20c6f02a5fbd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-caplyta-lumateperone-potential-123000377.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-caplyta-lumateperone-potential-123000377.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ITCI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T15:23:00+00:00",
    "headline": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
    "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
    "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
      "content": {
        "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
        "contentType": "STORY",
        "title": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
        "description": "",
        "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
        "pubDate": "2025-11-06T15:23:00Z",
        "displayTime": "2025-11-06T15:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]